- Home
- PHX vs LPTX Comparison
PHX vs LPTX Comparison
Compare PHX & LPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHX
- LPTX
- Stock Information
- Founded
- PHX 1926
- LPTX 2011
- Country
- PHX United States
- LPTX United States
- Employees
- PHX N/A
- LPTX N/A
- Industry
- PHX Oil & Gas Production
- LPTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PHX Energy
- LPTX Health Care
- Exchange
- PHX Nasdaq
- LPTX Nasdaq
- Market Cap
- PHX 137.2M
- LPTX 119.6M
- IPO Year
- PHX N/A
- LPTX N/A
- Fundamental
- Price
- PHX $3.99
- LPTX $2.46
- Analyst Decision
- PHX Strong Buy
- LPTX Strong Buy
- Analyst Count
- PHX 2
- LPTX 3
- Target Price
- PHX $4.90
- LPTX $7.50
- AVG Volume (30 Days)
- PHX 102.2K
- LPTX 335.2K
- Earning Date
- PHX 03-11-2025
- LPTX 11-13-2024
- Dividend Yield
- PHX 4.01%
- LPTX N/A
- EPS Growth
- PHX N/A
- LPTX N/A
- EPS
- PHX 0.13
- LPTX N/A
- Revenue
- PHX $31,939,771.00
- LPTX N/A
- Revenue This Year
- PHX $6.31
- LPTX N/A
- Revenue Next Year
- PHX $22.61
- LPTX N/A
- P/E Ratio
- PHX $31.06
- LPTX N/A
- Revenue Growth
- PHX N/A
- LPTX N/A
- 52 Week Low
- PHX $2.95
- LPTX $1.68
- 52 Week High
- PHX $4.15
- LPTX $4.79
- Technical
- Relative Strength Index (RSI)
- PHX 55.14
- LPTX 35.65
- Support Level
- PHX $3.92
- LPTX $2.88
- Resistance Level
- PHX $4.02
- LPTX $3.27
- Average True Range (ATR)
- PHX 0.09
- LPTX 0.30
- MACD
- PHX -0.00
- LPTX -0.08
- Stochastic Oscillator
- PHX 42.86
- LPTX 12.50
About PHX PHX Minerals Inc.
PHX Minerals Inc is an oil and natural gas mineral company that has employed a plan to shift the core of its business away from drilling and toward perpetual mineral and natural gas ownership. The company owns substantial mineral acreage, principally in Oklahoma, North Dakota, Texas, New Mexico, and Arkansas, but still maintains legacy interests in natural gas and oil properties that have retired operations. The revenues is derived from royalties granted from the production and sale of natural gas, oil and NGL, and the remaining portion of its revenues is derived from the production and sale of natural gas, oil and NGL on its working interests.
About LPTX Leap Therapeutics Inc.
Leap Therapeutics Inc is in developing targeted antibody therapies for cancer treatment, focusing on inhibiting tumor-promoting pathways, targeting cancer-specific cell surface molecules, and activating the immune system against cancer cells. The company's lead program, DKN-01, targets Dickkopf-related protein 1 (DKK1) and is in clinical trials for esophagogastric, gynecologic, and colorectal cancers. Their second program, FL-301, targets Claudin18.2-expressing cells. Additionally, the company has two preclinical antibody programs, FL-302 and FL-501, aimed at developing transformative cancer treatments. Operating as a single segment, the company's sole focus is on developing innovative drugs to address unmet needs in cancer therapy. .